Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25mg With Those of Enbrel®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy males, 20 to 45 years of age the moment of screening~* Body mass index is between 18.0 and 30.0 kg/m~Exclusion Criteria:~* The tuberculosis patient of latent tuberculosis patient~* Hypersensitivity response to the test and comparator drugs

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Enbrel, LBEC0101
- Group 2 (Type: EXPERIMENTAL): LBEC0101, Enbrel

Based on this trial design, predict the completion outcome and termination type (if applicable).